Lyra Therapeutics, Inc. (LYRA)
NASDAQ: LYRA · Real-Time Price · USD
0.0985
-0.0065 (-6.19%)
At close: Apr 28, 2025, 4:00 PM
0.1000
+0.0015 (1.52%)
After-hours: Apr 28, 2025, 4:56 PM EDT
Lyra Therapeutics Employees
Lyra Therapeutics had 30 employees as of December 31, 2024. The number of employees decreased by 58 or -65.91% compared to the previous year.
Employees
30
Change (1Y)
-58
Growth (1Y)
-65.91%
Revenue / Employee
$51,133
Profits / Employee
-$3,114,500
Market Cap
6.49M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
LYRA News
- 6 weeks ago - Lyra Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 months ago - Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 months ago - Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis - GlobeNewsWire
- 7 months ago - Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings - GlobeNewsWire
- 9 months ago - Lyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 1 year ago - Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital - GlobeNewsWire
- 1 year ago - Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis - GlobeNewsWire
- 1 year ago - Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire